List view / Grid view
31 July 2014 | By Novartis
Novartis published clinical trial results in the New England Journal of Medicine showing that KAE609 (cipargamin), a novel and potent antimalarial drug candidate...
30 July 2014 | By Pfizer
Pfizer Inc. announced that it has entered into a definitive agreement to acquire Baxter International Inc.’s portfolio of marketed vaccines for $635 million...
30 July 2014 | By Merck
Merck announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion recommending approval of a new, investigational intravenous formulation of NOXAFIL® (posaconazole)...
30 July 2014 | By AstraZeneca
AstraZeneca announced that it has entered an agreement to transfer to the company the rights to Almirall’s respiratory franchise for an initial consideration of $875 million on completion...
30 July 2014 | By kdm communications
Avacta Analytical has released a number of software updates for its innovative Optim® series of biophysical characterization instruments...
29 July 2014 | By Novo Nordisk
Novo Nordisk announced that the Committee for Medicinal Products for Human Use under the European Medicines Agency has adopted a positive opinion for Xultophy®...
29 July 2014 | By GlobalData
The launch of several drugs with “extraordinary blockbuster potential” will cause the acute coronary syndrome treatment market to more than triple in value...
29 July 2014 | By Janssen
... in all oral 12-week combination with sofosbuvir for genotype 1 chronic hepatitis C.
29 July 2014 | By Roche
Roche announced that the European Commission has approved Gazyvaro (obinutuzumab) in combination with chlorambucil chemotherapy...
29 July 2014 | By Johnson & Johnson
The U.S. Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA) for IMBRUVICA® (ibrutinib) capsules for the treatment of patients with chronic lymphocytic leukemia (CLL) who have received at least one prior therapy.1 The FDA also approved IMBRUVICA for CLL patients with del 17p,1 a genetic…
29 July 2014 | By Novartis
Novartis has announced the initial results of a large-scale vaccination campaign with Bexsero® to help protect against meningitis B within the Saguenay-Lac-Saint-Jean region of Québec, Canada...
Clinical laboratories around the world are helping to improve patient care while navigating an evolving healthcare environment. To help laboratories with increasing demands, Abbott (NYSE: ABT) is developing diagnostic solutions for today and tomorrow, which it will showcase during the American Association for Clinical Chemistry (AACC) Annual Meeting and Clinical…
28 July 2014 | By AstraZeneca
AstraZeneca announced it has entered into collaboration with Roche to develop a plasma-based companion diagnostic test to support AZD9291...
28 July 2014 | By Novartis
Alcon, the global leader in eye care and a division of Novartis, announced that Simbrinza® eye drops suspension (brinzolamide 10mg/mL and brimonidine tartrate 2mg/mL) has been approved by the European Commission...
28 July 2014 | By FT Live
The future is arriving fast for the life science industry...
